Media

Media

Recent News

  • Avivagen Finalizes Distribution Agreement with INPHILCO in the Philippines

    Deal creates new sales channel and revenue opportunities for OxC-betaTM Livestock with commercial farms and large integrated feed producers Ottawa, ON / Business Wire / February 18, 2020 / – Avivagen Inc.  (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune …Read More

  • Avivagen Announces CEO Update to Shareholders

    Ottawa, ON / Business Wire / January 29, 2020 / – Avivagen Inc. (TSXV:VIV, OTCQB: VIVXF) (“Avivagen”) announces its CEO update to shareholders. To our Shareholders: The past twelve months have been a period of exceptional accomplishment and achievement for Avivagen. As a Company, we have taken tremendous strides in the development and commercialization of …Read More

  • Avivagen Announces Closing of Additional $1.75 Million Private Placement

    Ottawa, ON /Business Wire/ January 27, 2020 / — Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to announce the successful second and final closing of its previously announced non-brokered private placement (the “Offering”).   …Read More

  • Mimi’s Rock Corp. and Avivagen Inc. Announce Launch of Dr Tobias Dog Chews on Amazon.com

    TORONTO, Jan. 23, 2020 /CNW/ – Mimi’s Rock Corp. (TSXV:MIMI) and Avivagen Inc. (TSXV:VIV) (collectively “the Companies”) are pleased to announce the Dr Tobias Dog Chews containing the proprietary Avivagen OxC-BetaTM additive are now available in the United States on Amazon and Drtobias.com. “We’ve been working closely with the Avivagen team to launch the first Dr Tobias branded product into …Read More

  • Avivagen Announces Update on Private Placement Process

    Ottawa, ON /Business Wire/ January 20, 2020 / — Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to provide an update on the status of its previously announced non-brokered private placement (the “Offering”) of …Read More

View All News Releases

Media Coverage

  • VICTAM Asia

    Avivagen CEO Interviewed at VICTAM Asia 2018 Conference

    Avivagen recently debuted at the VICTAM ASIA 2018 Conference in Bangkok, Thailand.

  • CEO Kym Anthony Interviewed by Uptick

    CEO Kym Anthony was interviewed by the penny stock news and trends podcast, Uptick Newswire.

    I think if people keep their eyes on the size of the prize, [they’ll see] the livestock market is in the billions of dollars; our share of that would be in the hundreds of millions if we roll out successfully. The human market is untouched. The companion animal market is also big. We’ve spent years proving it works; everyone agrees it works. Now is the time to roll it out commercially.

  • CTV: Growing resistance to antibiotics fuels market for alternative solutions

    CTV NEWS, TORONTO – A hundred years ago, a small wound could result in death if an infection spread. That could become reality again as the world threatens to return to a pre-antibiotic era due to antibiotic resistance.

    Some have pointed to the widespread use of antibiotics in livestock feed as a culprit, resulting in urgent calls to quell their use and find alternatives.

View All Media Coverage